Abstract
Experience with IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Frontline Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have